CN Patent

CN107645953B — 用于治疗贫血的组合物和方法

Assigned to Akebia Therapeutics Inc · Expires 2022-11-01 · 4y expired

What this patent protects

本文提供使用HIF脯氨酰羟化酶抑制剂在治疗或预防贫血中的特定剂量和给药方案，所述贫血为，例如，慢性肾病继发性或相关性的贫血、非透析依赖性慢性肾病继发性或相关性的贫血、化疗相关的或由化疗导致的贫血或与AIDS相关的贫血。

USPTO Abstract

本文提供使用HIF脯氨酰羟化酶抑制剂在治疗或预防贫血中的特定剂量和给药方案，所述贫血为，例如，慢性肾病继发性或相关性的贫血、非透析依赖性慢性肾病继发性或相关性的贫血、化疗相关的或由化疗导致的贫血或与AIDS相关的贫血。

Drugs covered by this patent

Patent Metadata

Patent number
CN107645953B
Jurisdiction
CN
Classification
—
Expires
2022-11-01
Drug substance claim
No
Drug product claim
No
Assignee
Akebia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.